Long-term outcomes among older patients following nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation for advanced hematologic malignancies
about
Bone marrow versus peripheral blood allogeneic haematopoietic stem cell transplantation for haematological malignancies in adultsReduced-intensity conditioning allogeneic hematopoietic-cell transplantation for older patients with acute myeloid leukemiaOlder patients with myeloma derive similar benefit from autologous transplantation.Long-term tolerance to kidney allografts after induced rejection of donor hematopoietic chimerism in a preclinical canine modelHematopoietic stem cell transplantation for hematologic malignancies in older adults: geriatric principles in the transplant clinic.The prognostic value of serum C-reactive protein, ferritin, and albumin prior to allogeneic transplantation for acute myeloid leukemia and myelodysplastic syndromesLate effects of blood and marrow transplantation.Increased age-associated mortality risk in HLA-mismatched hematopoietic stem cell transplantation.Costs of allogeneic hematopoietic cell transplantation using reduced intensity conditioning regimensAllotransplantation for patients age ≥40 years with non-Hodgkin lymphoma: encouraging progression-free survival.Conditioning regimens for hematopoietic cell transplantation: one size does not fit allGeriatric assessment to predict survival in older allogeneic hematopoietic cell transplantation recipients.Comorbidity-age index: a clinical measure of biologic age before allogeneic hematopoietic cell transplantation.Impact of donor age on outcome after allogeneic hematopoietic cell transplantation.Sex, age, race and intervention type in clinical studies of HIV cure: a systematic review.Non-myeloablative allogeneic hematopoietic cell transplantation following fludarabine plus 2 Gy TBI or ATG plus 8 Gy TLI: a phase II randomized study from the Belgian Hematological Society.Blood and marrow transplant clinical trials network state of the Science Symposium 2014Allogeneic hematopoietic cell transplantation in septuagenariansProspective Validation of the Predictive Power of the Hematopoietic Cell Transplantation Comorbidity Index: A Center for International Blood and Marrow Transplant Research StudyOutcomes of Nonmyeloablative HLA-Haploidentical Blood or Marrow Transplantation With High-Dose Post-Transplantation Cyclophosphamide in Older Adults.Comorbidities and outcomes: advancing the field comes at a price.Five-group cytogenetic risk classification, monosomal karyotype, and outcome after hematopoietic cell transplantation for MDS or acute leukemia evolving from MDS.Prognostic Importance of Pretransplant Functional Capacity After Allogeneic Hematopoietic Cell TransplantationOutcomes of Allogeneic Stem Cell Transplantation in Elderly Patients with Acute Myeloid Leukemia: A Systematic Review and Meta-analysis.Potential of whole-genome sequencing for determining risk and personalizing therapy: focus on AMLLast marrow standing: bone marrow transplantation for acquired bone marrow failure conditions.Incidence and Pattern of Graft-versus-Host Disease in Patients Undergoing Allogeneic Transplantation after Nonmyeloablative Conditioning with Total Lymphoid Irradiation and Antithymocyte GlobulinEfficacy and tolerability of anthracycline-based therapy in elderly patients with diffuse large B-cell lymphoma.Strategies to reduce relapse after allogeneic hematopoietic cell transplantation in acute myeloid leukemia.Frequency and Outcome of Graft versus Host Disease after Stem Cell Transplantation: A Six-Year Experience from a Tertiary Care Center in Pakistan.Nonrelapse mortality and mycophenolic acid exposure in nonmyeloablative hematopoietic cell transplantationQuantitative and qualitative differences in use and trends of hematopoietic stem cell transplantation: a Global Observational Study.High prevalence of potential drug interactions affecting mycophenolic acid pharmacokinetics in nonmyeloablative hematopoietic stem cell transplant recipients.Allogeneic hematopoietic cell transplantation in patients ⩾70 years: which patients may benefit?Risk assessment before allogeneic hematopoietic cell transplantation for older adults with acute myeloid leukemia.Pretransplant comorbidities maintain their impact on allogeneic stem cell transplantation outcome 5 years posttransplant: a retrospective study in a single german institution.Emerging immunotherapies in older adults with acute myeloid leukemia.Advances in conditioning regimens for older adults undergoing allogeneic stem cell transplantation to treat hematologic malignancies.To transplant or not: a dilemma for treatment of elderly AML patients in the twenty-first century.Hematopoietic stem cell transplantation for acute myeloid leukemia: to whom, when, and how.
P2860
Q24195048-50FA5C54-2777-4258-9332-0A2E696ED93BQ26744283-0D336ED1-9F12-4BB9-9B79-A413EFE52306Q30370038-93537DEF-BAC1-44F8-92CE-38FF9ECDAD1EQ30525173-1E48198D-6181-4765-9A9F-91267B9E304EQ33566684-A1AF107F-35CC-49F0-93AB-BF1D6F6C1290Q33573495-0A4DD152-8FC8-4A41-AD9E-B51133A863C5Q33574136-963730BF-6C6D-4326-B4BB-BC0FA046430EQ33574209-C53EF3AD-4275-4B28-8FA2-F461657FC50EQ33699602-F5E95D23-1389-4099-885C-1526ADAC1290Q33756719-816EE221-FE07-489A-9E87-4AA7FD16D310Q33917170-49092CE1-A47C-472B-BBA2-3FFDC4D2AB07Q33978945-4AF608CF-4EF8-462C-A756-7B7682E4779AQ34260505-12E91642-7AFC-47B6-B0FF-EFE6222734F6Q34859147-D7195B35-348D-403B-831D-3A8B5E49E941Q34870233-3E58B533-55CE-4B7A-9F08-437D9EAB9076Q35095722-C4C03950-DD57-4A47-8753-C8EBCAD8CA47Q35591760-78DC1FA0-BD59-4E27-BA75-CCACE9B5141DQ35766718-84EE6BA1-31CA-4785-81BE-2AD3D9A7A392Q35882830-34DBC2CC-A5D9-4734-B8C8-66DEFE1BDDA7Q36090971-DE63FE12-783F-4929-964E-8528B1B2FCEDQ36097676-63DD0764-4142-418A-B713-BE3798820834Q36339459-B90A3F1A-438E-4FE9-96D8-D7C40DF990D3Q36478727-C6F6CD65-BE0E-4552-9FF8-6E41FAF62E70Q36723291-E1889717-89FF-42EC-BC67-D09F241B4B39Q36797201-D825E34B-8508-4480-867C-9C344EC55C4FQ36806501-86F4693A-0EED-4448-BF6C-D23134B68288Q36838087-DC201FCB-6280-4A79-ACE7-99D5EA67FA73Q36908665-21E267FC-0E84-40F0-BCA4-7B8CC12354C4Q37000485-ACA23C34-E1B2-4D1D-AC11-AD2F46F1DEBAQ37015550-7B2498C2-C3D3-4679-888C-F3356E383A41Q37038889-05A1CB8E-EC25-4CD5-BA1B-A0F1CBD0E4C0Q37060673-524B396B-6E04-4ABF-93E4-D0468EBD1F70Q37135382-A32745B6-BCD5-43ED-A61C-6DD168A90E3AQ37270993-2B8FCB53-552E-4E71-AD0B-E815B042BFE8Q37419348-5F644575-E5A8-4EEF-8BB7-0A14DB0942F7Q37657429-AE82D7E9-9F78-4ED0-8125-F5A7C7BD18AEQ38075407-FF7A9E0E-39DD-44F8-9555-A6645A40FE64Q38095833-5B3BD64B-D094-4967-9479-2349A76FBA1DQ38104287-78211B17-156A-4D4D-99BD-1855B74D12D4Q38130168-8685C5F9-1FD0-44A5-B3EB-316FA952040F
P2860
Long-term outcomes among older patients following nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation for advanced hematologic malignancies
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Long-term outcomes among older ...... anced hematologic malignancies
@ast
Long-term outcomes among older ...... anced hematologic malignancies
@en
type
label
Long-term outcomes among older ...... anced hematologic malignancies
@ast
Long-term outcomes among older ...... anced hematologic malignancies
@en
prefLabel
Long-term outcomes among older ...... anced hematologic malignancies
@ast
Long-term outcomes among older ...... anced hematologic malignancies
@en
P2093
P2860
P50
P356
P1476
Long-term outcomes among older ...... anced hematologic malignancies
@en
P2093
Amelia Langston
Andrew Yeager
Benedetto Bruno
Dietger Niederwieser
Edward Agura
Finn Bo Petersen
Firoozeh Sahebi
Georg N Franke
George E Georges
Ginna G Laport
P2860
P304
P356
10.1001/JAMA.2011.1558
P407
P577
2011-11-01T00:00:00Z